Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 86,408	$ 184,434
Accounts receivable	1,317	10,255
Prepaid expenses	6,622	4,362
Other current assets	7,796	2,191
Marketable securities	122,575	126,728
Short term investments	192,912	56,627
TOTAL CURRENT ASSETS	417,630	384,597
Property and equipment, net	54,888	48,675
Intangible assets, net	12,813	13,663
Long term investments	201,590	245,595
Right-of-use assets	16,379	17,346
Other assets	275	272
TOTAL ASSETS	703,575	710,148
CURRENT LIABILITIES
Accounts payable	10,603	9,457
Accrued expenses	23,710	14,001
Accrued payroll and benefits	3,765	9,773
Lease liabilities	2,910	2,250
Deferred revenue	97,869	111,055
TOTAL CURRENT LIABILITIES	138,857	146,536
LONG-TERM LIABILITIES
Lease liabilities, net of current portion	22,698	23,295
Deferred revenue, net of current portion	89,754	131,495
TOTAL LONG-TERM LIABILITIES	112,452	154,790
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders’ equity:
Common stock, $0.001 par value; 145,000 shares authorized; 105,702 and 104,327 shares issued and outstanding as of March 31, 2022 and September 30, 2021, respectively	198	197
Additional paid-in capital	1,115,373	1,053,386
Accumulated other comprehensive loss	(107)	(69)
Accumulated deficit	(663,198)	(644,692)
TOTAL STOCKHOLDERS’ EQUITY	452,266	408,822
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 703,575	$ 710,148